Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging

项目2：细胞质染色质片段（CCF）作为肝癌的驱动因素和衰老过程中的干预目标

• 批准号: 10698106
• 负责人: PETER D. ADAMS
• 金额: $ 41.16万
• 依托单位: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-15 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10698106
• 关键词: Acute; Age; Aging; Antitumor Response; Automobile Driving; Autophagocytosis; Benign; Bulla; Cell Aging; Cell Nucleus; Cell Proliferation; Cells; Cellular Stress; Characteristics; Chromatin; Chronic; Cirrhosis; Cytoplasm; DNA; Data; Diet; Disease; Disease Outcome; Family; Fatty Liver; Fibrosis; Genes; Hepatocyte; Human Characteristics; Immune; Immune checkpoint inhibitor; Immunosuppression; Incidence; Inflammation; Inflammatory; Interferon Activation; Interferons; Intervention; JNK-activating protein kinase; Knockout Mice; Liver; Malignant neoplasm of liver; Mediating; Metabolism; Mitochondria; Molecular; Molecular Profiling; Mus; Mutation; NF-kappa B; Neoplasms; Oncogenes; Oncogenic; Organism; Pathway interactions; Phenotype; Predisposition; Prevention strategy; Primary carcinoma of the liver cells; Process; Proliferating; Resistance; Risk; Risk Factors; Role; Severities; Signal Pathway; Signal Transduction; Sirolimus; Source; Testing; Tissues; Tumor Suppressor Genes; Up-Regulation; Viral; Virus; adaptive immunity; age related; aged; candidate selection; cell transformation; chronic liver disease; cytokine; epigenome; genetic manipulation; immune clearance; immunosuppressed; in vivo; indexing; inhibitor; liver cancer prevention; mitochondrial dysfunction; neoplastic; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel therapeutics; nuclease; permissiveness; prevent; programmed cell death ligand 1; response; senescence; tumor; tumor-immune system interactions; tumorigenesis; tumorigenic

PROJECT SUMMARY – PROJECT 2 The incidences of liver cancer (primarily hepatocellular carcinoma (HCC)) are increasing and disease outcome is poor. Consequently, there is an urgent need for new therapies and preventive strategies. Age is a major risk for HCC and non-alcoholic fatty liver disease (NAFLD). NAFLD is a chronic liver disease that encompasses a progressive range of disorders of increasing severity and risk of HCC, from benign fatty liver (steatosis), to inflammatory non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis. Aging is accompanied by many molecular, cellular and tissue changes that are candidate drivers of NAFLD and HCC, including the “hallmarks of aging” that are dysregulated with age in diverse tissues and organisms; for example, changes to mitochondria, metabolism, the epigenome, accumulation of senescent cells, inflammation and immune changes. Cell senescence is caused by a range of cellular stresses and characterized by an irreversible proliferation arrest and a potent pro-inflammatory phenotype, the senescence-associated secretory phenotype (SASP). Recently, we showed that in senescent cells, mitochondria dysfunction signals to evict fragments of chromatin from the nucleus into the cytoplasm (cytoplasmic chromatin fragments (CCF)) via a nucleus-to- cytoplasmic blebbing process. CCF are sensed by the anti-viral cytoplasmic DNA sensing apparatus to activate NFkB and the SASP. The SASP of senescent cells includes interferons, a family of cytokines involved in cell intrinsic anti-viral mechanisms, control of cell proliferation, inflammation and adaptive immunity, and tumor suppressive and oncogenic processes. Although SASP and acute IFN signaling have important benefits, chronic SASP and IFN signaling can be detrimental. As a source of chronic inflammation, SASP promotes tissue aging and disease, including liver cancer. Chronic IFN signaling can promote immunosuppression, in part by upregulation of immune checkpoint inhibitors, such as PD-L1. Based on unpublished data, we hypothesize that accumulation of CCF in aged and/or senescent liver hepatocytes drives chronic activation of IFN signaling, expression of IFN target genes and immune checkpoint inhibitors, such as PD-L1. We further hypothesize that this, in turn, generates an immunosuppressed liver microenvironment that is permissive for transformation of old hepatocytes. By antagonizing this immunosuppressive signaling pathway, we hypothesize that several different types of intervention can prevent liver cancer during aging. Completion of these Specific Aims will promote novel interventions to prevent HCC.

项目概要-项目2 肝癌（主要是肝细胞癌（HCC））的发病率正在增加， 差因此，迫切需要新的治疗方法和预防策略。年龄是主要风险 HCC和非酒精性脂肪肝（NAFLD）。NAFLD是一种慢性肝病， 从良性脂肪肝（脂肪变性）到HCC严重程度和风险增加的疾病进展范围， 炎性非酒精性脂肪性肝炎（NASH）、纤维化和肝硬化。衰老伴随着许多 分子、细胞和组织的变化是NAFLD和HCC的候选驱动因素，包括“标志 在不同的组织和生物体中，随着年龄的增长而失调的“衰老”;例如，线粒体的变化， 代谢，表观基因组，衰老细胞的积累，炎症和免疫变化。 细胞衰老是由一系列细胞应激引起的，其特征在于不可逆的衰老。 增殖停滞和有效的促炎表型，衰老相关的分泌表型 （南非战略规划署）。最近，我们发现，在衰老细胞中，线粒体功能障碍的信号驱逐片段， 染色质从细胞核进入细胞质（细胞质染色质片段（CCF）），通过细胞核- 胞质起泡过程CCF被抗病毒细胞质DNA传感装置感测以激活 NFkB和SASP。衰老细胞的SASP包括干扰素，干扰素是参与细胞衰老的细胞因子家族。 内在抗病毒机制、细胞增殖控制、炎症和适应性免疫以及肿瘤 抑制和致癌过程。尽管SASP和急性IFN信号传导具有重要益处，但慢性 SASP和IFN信号传导可能是有害的。作为慢性炎症的来源，SASP促进组织老化 和疾病，包括肝癌。慢性IFN信号传导可以促进免疫抑制，部分通过 上调免疫检查点抑制剂，如PD-L1。 基于未发表的数据，我们假设CCF在老年和/或衰老肝脏中的蓄积 肝细胞驱动IFN信号传导、IFN靶基因表达和免疫检查点的慢性激活 抑制剂，如PD-L1。我们进一步假设，这反过来又产生了免疫抑制的肝脏， 这是允许旧肝细胞转化的微环境。通过对抗这个 免疫抑制信号通路，我们假设几种不同类型的干预可以防止 肝癌在衰老过程中这些具体目标的完成将促进新的干预措施，以防止肝癌。